ImmunoMind

Bring forth the synergy between biologists, medical scientists, data scientists and bioinformaticians

ImmunoMind (graduated from UC Berkeley SkyDeck) helps companies and medical centres design and produce safer and more effective CAR-T and other Cell Therapies, leveraging a proprietary multi-omics database of immune cells and AI. This collaboration connects eLabNext users to the ImmunoMind platform and enhances reporting in eLabJournal by using results from multi-omics-driven drug development and manufacturing. The ImmunoMind add-on identifies both cell subpopulations (e.g. Tscm, Tcm, Tem, Treg, NK, gdT cells) and their characteristics (e.g. exhaustion, senescence, activation) to create a comprehensive profile of CAR-T and other Cell Therapy products.

• The profile can help select the most effective design and dosage for CAR-T, improve QC and SOP to select T-cell subsets (such as Tscm and T-cell precursors), assess exhaustion and persistence of CAR-T cells in vitro and in vivo, and more.
• The platform supports Go/No-Go decision-making and reduces the risk of immunotherapy development and manufacturing.